Emfret Analytics, a privately-held biotech developing platelet receptor–targeting antibodies for research, diagnostic and ...

For tens of thousands of children worldwide, idiopathic nephrotic syndrome (INS), a chronic and debilitating kidney disease, ...

Israel-based Teva Pharmaceutical Industries today announced three milestones in its biosimilar portfolio, demonstrating ...

Fund and Thailand Science Research and Innovation (TSRI) have signed a Memorandum of Understanding (MOU) to strengthen their ...

New findings have been presented on a couple of late-stage candidates in hidradenitis suppurativa (HS) at the 2026 American ...

As Parkinson’s disease (PD) awareness month approaches this April, analysis of the global drug landscape reveals an evolving research focus in PD.

US physician and biochemist Robert Malone has stepped down from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices, after a federal court ruling ...

The USA remains the outlier among wealthy drug markets. OECD data for 2023 put US retail pharmaceutical spending at $1,713 per person, against an OECD average of $766. Germany was at $1,158 and ...

Swiss biotech Idorsia’s share rose 5.7% to 3.24 francs in early trading, after it announced positive top-line results from its Phase II dose-finding study evaluating 10mg, 25mg and 50mg doses of ...

Otsuka Pharmaceutical Development & Commercialization, a subsidiary of Japan’s Otsuka, announced new analyses from the Phase III VISIONARY trial evaluating Voyxact (sibeprenlimab-szsi) in adults with ...

US biotech Biogen has announced positive results from the Phase II part of the AMETHYST Phase II/III study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE).

UK pharma major AstraZeneca's reported positive outcome to two Phase III chronic obstructive pulmonary disease (COPD) studies ...